Table 2.
The outcomes of concomitant and sequential therapies
Concomitant therapy | Sequential therapy | p-value | |
---|---|---|---|
Eradication rate | |||
Intention-to-treat | 107/115 (93%) | 108/117 (92.3%) | 0.83 |
Per-protocol | 107/115(93%) | 108/116 (93.1%) | 0.99 |
Compliance | 113/115 (98.2%) | 112/117 (95.7%) | 0.26 |
Side effect | 31/115 (26.9%) | 36/117 (30.7%) | 0.40 |
Diarrhea | 3/115 (2.6%) | 2/117 (1.7%) | 0.64 |
Constipation | 0 | 0 | - |
Abdominal pain | 3/115 (2.6%) | 5/117 (4.3%) | 0.49 |
Anorexia | 4/115 (3.5%) | 2/117 (1.7%) | 0.40 |
Nausea | 9/115 (7.8%) | 3/117 (2.6%) | 0.07 |
Vomiting | 2/115 (1.7%) | 2/117 (1.7%) | 0.99 |
Skin rash | 3/115 (2.6%) | 1/117 (0.8%) | 0.30 |
Headache | 5/115 (4.3%) | 5/117 (4.3%) | 0.98 |
Dizziness | 13/115 (11.3%) | 10/117(8.5%) | 0.48 |
Bad taste | 18/115 (15.7%) | 12/117 (10.3%) | 0.22 |
Fatigue | 5/115 (4.3%) | 13/117 (11.1%) | 0.05 |